Protalix BioTherapeutics, Inc. 4
4 · Protalix BioTherapeutics, Inc. · Filed Sep 16, 2016
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2016-09-15−122,162→ 0 totalExercise: $0.00→ Common Stock (122,162 underlying) - Exercise/Conversion
Common Stock
2016-09-15$0.00/sh+122,162$122→ 585,916 total
Holdings
- 210,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., issued under its 2006 Stock Incentive Plan, as amended June 17, 2012 (the "Plan"), all of which have vested. Vested restricted shares are subject to a lock-up for a 24-month period from the date of vesting. Notwithstanding the foregoing and subject to certain exceptions, the lock-up period will terminate immediately upon a Change in Control, as defined in the Plan.
- [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
- [F3]Represents exercise of all stock underlying the derivative security.
- [F4]Does not include options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018; options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and options to purchase 275,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.